Upgrade to cardiac resynchronization therapy with a defibrillator (CRT-D) reduces morbidity and mortality and improves left ventricular (LV) reverse remodeling compared to an implantable cardioverter-defibrillator (ICD) in select patients with heart failure and reduced ejection fraction (HFrEF) and intermittent or permanent right ventricular (RV) pacing, according to late breaking research presented in a Hot Line session August 26 at ESC Congress 2023.
Upgrade to cardiac resynchronization therapy with a defibrillator reduces morbidity and mortality and improves left ventricular reverse remodeling compared to an implantable cardioverter-defibrillator in select patients with heart failure and reduced ejection fraction and intermittent or permanent right ventricular pacing, according to late breaking research presented in a Hot Line session August 26 atApproximately one million conventional pacemakers or ICDs are implanted each year worldwide.
Patients were excluded if they were eligible for CRT according to current guidelines, had severe RV dilation, had severe valvular heart disease, had severe renal impairment or had survived anParticipants were randomly assigned to receive a CRT-D upgrade or ICD in a 3:2 ratio. For patients with an ICD at baseline who were assigned to the ICD arm, there were two options at the physician's discretion: 1) no procedure; or 2) CRT-D upgrade with the CRT function turned off.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
CRT-D upgrade reduces morbidity and mortality in HFrEF patients with RV pacingUpgrade to cardiac resynchronization therapy with a defibrillator (CRT-D) reduces morbidity and mortality and improves left ventricular (LV) reverse remodeling compared to an implantable cardioverter-defibrillator (ICD) in select patients with heart failure and reduced ejection fraction (HFrEF) and intermittent or permanent right ventricular (RV) pacing, according to late breaking research presented in a Hot Line session today at ESC Congress 2023.
Lire la suite »
PROFID EHRA trial to assess the potential benefit of ICD therapy in myocardial infarction survivorsIs the routine implantation of an implantable cardioverter defibrillator (ICD) in myocardial infarction survivors with heart failure still an adequate therapy for prevention of sudden cardiac death?
Lire la suite »
Study shows benefit of traditional Chinese medicine for heart failureThe traditional Chinese medicine qiliqiangxin reduces hospitalization for heart failure and cardiovascular death in patients with heart failure and a reduced ejection fraction (HFrEF), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.
Lire la suite »
First randomized trial of traditional Chinese medicine for heart failure shows benefitThe traditional Chinese medicine qiliqiangxin reduces hospitalization for heart failure and cardiovascular death in patients with heart failure and a reduced ejection fraction (HFrEF), according to late breaking research presented in a Hot Line session August 26 at ESC Congress 2023.
Lire la suite »
Trial of ferric carboxymaltose in heart failure does not meet primary endpointFerric carboxymaltose (FCM) did not improve a hierarchical outcome of death, heart failure hospitalizations and exercise function in ambulatory patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency, according to late breaking research presented in a Hot Line session August 26 at ESC Congress 2023.
Lire la suite »